All In Biotech

Drug Trial Radar · NCT04923126

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

SJ901: Phase 1/2 Evaluation of Single Agent Mirdametinib (PD-0325901), a Brain-Penetrant MEK1/2 Inhibitor, for the Treatment of Children, Adolescents, and Young Adults With Low-Grade Glioma

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Jun 21, 2021

Primary completion

Jun 2031

Study completion Jun 2031

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
First posted
Jun 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 24 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).

Conditions

  • Low-Grade Glioma
  • Recurrent Low-Grade Glioma
  • Progressive Low-Grade Glioma

Interventions

  • MirdametinibDrug

    By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Estimate the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of mirdametinib dosed twice daily on a continuous schedule in pediatric patients with progressive or recurrent low-grade glioma.Time frame: 1 month after start of mirdametinib treatment
  2. Phase 1: Determine the safety and tolerability of mirdametinib dosed twice daily on a continuous schedule in pediatric patients with progressive or recurrent low-grade glioma.Time frame: Up to 25 months after start of mirdametinib treatment
  3. Characterize the maximum plasma concentration and area under the concentration-time curve (AUC0-8h) of mirdametinib.Time frame: Course 1: Days 1 and 15
  4. Phase 2, Cohort 1: Objective response rate observed anytime during active treatment and sustained for at least 8 weeksTime frame: Up to 24 months after start of mirdametinib treatment
  5. Phase 2, Cohort 2: Objective response rate observed anytime during active treatment and sustained for at least 8 weeksTime frame: Up to 24 months after start of mirdametinib treatment
  6. Phase 2, Cohort 3a: Estimate 1-year disease stabilization rateTime frame: Up to 12 months (slight departures from this timing allowed based on MRI screening) after start of mirdamentinib treatment
  7. Phase 2, Cohort 3b: Estimate 6-month disease stabilization rateTime frame: Up to 6 months (slight departures from this timing allowed based on MRI screening) after start of mirdametinib treatment
  8. Describe the toxicity profile of mirdametinib by cohort.Time frame: Up to 25 months after start of mirdametinib treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Jude Children's Research Hospital

    Memphis, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.